Recommendations
11.12	Conduct postmarketing surveillance data collection using well-designed, large observational studies and registries.
11.13	Share clinical trial data to allow subsequent individual patient data analyses, meta-analyses, and subgroup analyses; updating of OPGs; and validation of decision-making tools, such as the WIfI system and GLASS.